1) Pentoxifylline
已酮可可碱
1.
Hemorheologic Changes in Experimental High-Voltage Electrical Burns and the Therapeutic Effects of Pentoxifylline;
实验高压电烧伤血液流变学变化及已酮可可碱的治疗作用
2.
Expression of heat shock protein 70 in myocardial tissue in rats with endotoxemia and effects of pentoxifylline;
热休克蛋白70在内毒素血症大鼠心肌中的表达及已酮可可碱的影响
3.
Effect of pentoxifylline on neuron specific enolase of rats after global cerebral ischemia-Reperfusion;
已酮可可碱对大鼠全脑缺血再灌注后神经元特异性烯醇化酶的影响
2) 1-(5-Oxohexyl) theobromine
已酮可可豆碱
3) Pentoxifylline
己酮可可碱
1.
Pentoxifylline Modified Release Capsules' Preparation and Its in Vitro Drug Release Characteristics;
己酮可可碱缓释胶囊的研制及其体外释药特性考察
2.
Determination the Release Rate of Pentoxifylline Sustained Release Capsules in vitro;
己酮可可碱缓释胶囊的制备及体外释放度检测
3.
Long-term effects of pentoxifylline in patients with congestive heart failure;
己酮可可碱治疗慢性充血性心力衰竭患者的远期疗效
4) PTX
己酮可可碱
1.
PTX and lipoPGE1 relieve ischemia and reperfusion injury of abdominal aorta in rats;
己酮可可碱和PGE1缓解大鼠腹主动脉缺血/再灌注损伤
2.
Objective:Focal cerebral ischemia model in rat was established in order to investigate the potential protective effect and possible mechanism of PTX for lessening the focal cerebral ischemia injury.
目的:建立大鼠局灶性脑缺血模型,观察己酮可可碱对大鼠局灶性脑缺血保护作用,并探讨其减轻局灶性脑缺血损伤的机制。
5) Pentoxifylline (PTX)
己酮可可碱(PTX)
6) Pentoxifylline Sustained Release Tablets
己酮可可碱缓释片
补充资料：已酮可可碱
分子式：C13H18N4O3
分子量：278.31
CAS号：6493-05-6
性质：白色针状结晶。熔点105℃。易溶于水、苯、乙醇、氯仿，微溶于乙醇。无臭，味苦。
制备方法：由1，3-溴氯丙烷与乙酰乙酸乙酯在80℃左右环合得到2-甲基-3-乙氧羰基-5，6-二氢吡喃，再将其开环、溴化生成1-溴-5-已酮，然后与可可碱钠盐缩合制成已酮可可碱。
用途：该品为血管扩张药，能改善脑和四肢的血液循环。小鼠口服LD50为1385mg/kg。
分子量：278.31
CAS号：6493-05-6
性质：白色针状结晶。熔点105℃。易溶于水、苯、乙醇、氯仿，微溶于乙醇。无臭，味苦。
制备方法：由1，3-溴氯丙烷与乙酰乙酸乙酯在80℃左右环合得到2-甲基-3-乙氧羰基-5，6-二氢吡喃，再将其开环、溴化生成1-溴-5-已酮，然后与可可碱钠盐缩合制成已酮可可碱。
用途：该品为血管扩张药，能改善脑和四肢的血液循环。小鼠口服LD50为1385mg/kg。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条